Viruses as antitumor weapons: defining conditions for tumor remission.

Recent research has indicated that viruses specifically infecting tumor cells could be used as an alternative therapeutic approach in cancer patients. A particular example is the adenovirus ONYX-015, which has entered clinical trials in the context of head and neck cancer. Successful therapy crucially requires an understanding about how viral and host parameters influence tumor load. The interactions between the growing tumor, the replicating virus, and possible immune responses are multifactorial and nonlinear. Hence, a complete understanding of how virus and host characteristics influence the outcome of therapy requires mathematical models. In this study, such mathematical models are presented and analyzed. The study investigates three possible scenarios that could be relevant for therapy: (a) viral cytotoxicity alone kills tumor cells; (b) a virus-specific lytic CTL response contributes to killing of infected tumor cells; (c) the virus elicits immunostimulatory signals within the tumor that promote the development of tumor-specific CTL. The models precisely define conditions required for successful therapy. They identify the parameters that need to be measured and modulated to evaluate and refine the existing therapy regimes.

[1]  F. McCormick,et al.  New molecular targets for cancer therapy. , 1996, Scientific American.

[2]  A. Asai,et al.  Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas. , 1999, Cancer research.

[3]  D. Kirschner,et al.  Modeling immunotherapy of the tumor – immune interaction , 1998, Journal of mathematical biology.

[4]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[5]  D. Kirn,et al.  ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents , 1997, Nature Medicine.

[6]  C. Murray.  Tumour dormancy: not so sleepy after all , 1995, Nature Medicine.

[7]  R K Jain,et al.  Primary tumor size-dependent inhibition of angiogenesis at a secondary site: an intravital microscopic study in mice. , 1998, Cancer research.

[8]  P. Klenerman,et al.  Immune surveillance against a solid tumor fails because of immunological ignorance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Nicola Bellomo,et al.  A Survey of Models for Tumor-Immune System Dynamics , 1996 .

[10]  Cheng-Ta Yang,et al.  ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. , 2000, Cancer research.

[11]  A. Braithwaite,et al.  Efficient induction of cell death by adenoviruses requires binding of E1B55k and p53. , 2000, Cancer research.

[12]  H. Rammensee,et al.  Problem solving for tumor immunotherapy , 2000, Nature Biotechnology.

[13]  D. Kirn,et al.  Replicating viruses as selective cancer therapeutics. , 1996, Molecular medicine today.

[14]  D. Kirn,et al.  Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. , 1999, Cancer research.

[15]  D. Kirn,et al.  Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: Intratumoral spread and distribution effects , 1999, Cancer Gene Therapy.

[16]  F. McCormick,et al.  ONYX-015: Clinical data are encouraging , 1998, Nature Medicine.

[17]  P. Matzinger,et al.  Is cancer dangerous to the immune system? , 1996, Seminars in immunology.

[18]  M. Gulley,et al.  A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  P. Matzinger,et al.  An innate sense of danger. , 1998, Seminars in immunology.

[20]  M. Gulley,et al.  Erratum: A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer (Clinical Cancer Research (2000) 6 (798-806)) , 2000 .

[21]  R J D B,et al.  Target Cell Limited and Immune Control Models of HIV Infection : A Comparison , 1998 .

[22]  D. Kirn,et al.  In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. , 2000, Cancer research.

[23]  E. T. Gawlinski,et al.  A reaction-diffusion model of cancer invasion. , 1996, Cancer research.

[24]  J. H. Kim,et al.  A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. , 1998, Human gene therapy.

[25]  I. Tannock,et al.  A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.

[26]  R. Gatenby,et al.  Application of competition theory to tumour growth: implications for tumour biology and treatment. , 1996, European journal of cancer.

[27]  Anthony R. Hall,et al.  p53-dependent cell death/apoptosis is required for a productive adenovirus infection , 1998, Nature Medicine.